Mersana Therapeutics Price to Free Cash Flow Ratio 2016-2024 | MRSN

Mersana Therapeutics price to free cash flow ratio from 2016 to 2024. Price to free cash flow ratio can be defined as

Mersana Therapeutics Price to Free Cash Flow Ratio 2016-2024 | MRSN

Mersana Therapeutics price to free cash flow ratio from 2016 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$170.6B
Vertex Pharmaceuticals (VRTX)$117.1B
Regeneron Pharmaceuticals (REGN)$111.8B
Bristol Myers Squibb (BMY)$109.9B
Gilead Sciences (GILD)$104.8B
CSL (CSLLY)$95.8B
GSK (GSK)$79.5B
Alnylam Pharmaceuticals (ALNY)$34.6B
Argenex SE (ARGX)$32.5B
BioNTech SE (BNTX)$28.5B
Biogen (BIIB)$26.9B
Moderna (MRNA)$23.5B
BeiGene (BGNE)$22.7B
Illumina (ILMN)$21.7B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$12.9B
Incyte (INCY)$12.9B
Vaxcyte (PCVX)$12.4B
Exact Sciences (EXAS)$12.3B
Insmed (INSM)$12.3B
Bio-Techne Corp (TECH)$11.7B
Sarepta Therapeutics (SRPT)$11.3B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.7B
Roivant Sciences (ROIV)$8.3B
Ascendis Pharma (ASND)$8.2B
Repligen (RGEN)$7.8B
Revolution Medicines (RVMD)$7.7B
Halozyme Therapeutics (HALO)$7.7B